Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Open access
Gounder, Mrinal M., Zer, Alona, Tap, William D., Salah, Samer, Dickson, Mark A., Gupta, Abha A., Keohan, Mary Louise, Loong, Herbert H., D’Angelo, Sandra P., Baker, Stephanie, Condy, Mercedes, Nyquist-Schultz, Kjirsten, Tanner, Lanier, Erinjeri, Joseph P., Jasmine, Francis H., Friedlander, Sharon, Carlson, Robert, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Ellis, Joel, Kauffman, Michael, Shacham, Sharon, Schwartz, Gary K., Abdul Razak, Albiruni Ryan·2016·Journal of Clinical Oncology

Abstract

Purpose: We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. Patients and Methods: Fifty-four patients were treated with oral selinexor twice per week (on days 1 and 3) at one of three doses (30 mg/m 2 , 50 mg/m 2 , or flat dose of 60 mg) either continuously or on a schedule of 3 weeks on, 1 week off. PK analysis was performed under fasting and fed states (low v high fat content) and using various formulations of selinexor (tablet, capsule, or suspension). Tumor biopsies before and during treatment were evaluated for pharmacodynamic changes. Results: The most commonly reported drug-related adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed with supportive care. Commonly reported grade 3 or 4 toxicities were fatigue, thrombocytopenia, anemia, lymphopenia, and leukopenia. Selinexor was significantly better tolerated when administered as a flat dose on an intermittent schedule. PK analysis of selinexor revealed a clinically insignificant increase (approximately 15% to 20%) in drug exposure when taken with food. Immunohistochemical analysis of paired tumor biopsies revealed increased nuclear accumulation of tumor suppressor proteins, decreased cell proliferation, increased apoptosis, and stromal deposition. Of the 52 patients evaluable for response, none experienced an objective response by RECIST (version 1.1); however, 17 (33%) showed durable (≥ 4 months) stable disease, including seven (47%) of 15 evaluable patients with dedifferentiated liposarcoma. Conclusion: Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.6346

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 164

Metadata

Authors
Gounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., Condy, M., Nyquist-Schultz, K., Tanner, L., Erinjeri, J. P., Jasmine, F. H., Friedlander, S., Carlson, R., Unger, T. J., Saint-Martin, J.-R., Rashal, T., Ellis, J., Kauffman, M., Shacham, S., Schwartz, G. K., & Abdul Razak, A. R.
Venue
Journal of Clinical Oncology
Published
2016-09-10
Volume
34
Issue
26
Pages
3166-3174
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2495597122
Cited by
164
References
1
FWCI
15.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. https://app.cochat.ai/papers/10.1200/jco.2016.67.6346
The paper
Gounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., Condy, M., Nyquist-Schultz, K., Tanner, L., Erinjeri, J. P., Jasmine, F. H., Friedlander, S., Carlson, R., Unger, T. J., Saint-Martin, J.-R., . . . Abdul Razak, A. R. (2016). Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.6346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.